Colan Totte.Co (7792) Fundamentals 2026 — P/E 9.8x, Revenue Analysis | SniperIQ
Colan Totte.Co (7792) is a JP-listed Healthcare company in Medical - Devices with a market capitalization of ¥13.3B, trading at ¥1460.00 on the JPX. This SniperIQ fundamentals page covers Colan Totte.Co's valuation (P/E 9.8x, P/B 2.4x), profitability (net margin 16.9%), revenue (¥6.9B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Colan Totte.Co's market cap?
Colan Totte.Co (7792) has a market capitalization of approximately ¥13.3B, trading at ¥1460.00 on the JPX. Market cap moves with the live share price.
What is Colan Totte.Co's P/E ratio?
Colan Totte.Co's trailing twelve-month P/E ratio is 9.8x, with a price-to-book (P/B) of 2.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Colan Totte.Co?
Colan Totte.Co runs a net profit margin of 16.9%, a gross margin of 68.0%, and an operating margin of 24.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Colan Totte.Co generate?
Colan Totte.Co reported revenue of ¥6.9B for fiscal year 2025, with net income of ¥1.3B and earnings per share (EPS) of 146.49. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Colan Totte.Co pay a dividend?
Colan Totte.Co offers a trailing dividend yield of about 2.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Colan Totte.Co financially healthy?
Colan Totte.Co carries a debt-to-equity ratio of 0.00x and a current ratio of 3.09x, with a market beta of 0.69. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Colan Totte.Co a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Colan Totte.Co (7792) the key facts are: market cap ¥13.3B, P/E 9.8x, revenue ¥6.9B, 52-week range 1350-1596. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Colan Totte.Co's full fundamentals live
Get Colan Totte.Co's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.